Vir Biotechnology
233 hedge funds and large institutions have $604M invested in Vir Biotechnology in 2025 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 74 increasing their positions, 71 reducing their positions, and 26 closing their positions.
100% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 26
12% more funds holding
Funds holding: 208 → 233 (+25)
3.53% more ownership
Funds ownership: 64.47% → 68% (+3.5%)
4% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 71
3% more call options, than puts
Call options by funds: $1.87M | Put options by funds: $1.81M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $652M → $604M (-$47.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.47M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.84M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$12.2M |
| 2 |
Millennium Management
New York
|
-$11.4M |
| 3 |
O
OrbiMed
New York
|
-$8.63M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.23M |
| 5 |
SCM
Sio Capital Management
New York
|
-$5.17M |
VIR Hedge Fund Activity: Q1 2025 in Review
233 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2025, worth a combined $604M — down 7.3% from $652M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new VIR positions and 26 closed out — a net gain of 26 holders — while 74 added to existing stakes and 71 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.6M. The largest seller was JP Morgan Chase, cutting an estimated $12.2M.
- 233 institutional investors held Vir Biotechnology (VIR) as of Q1 2025, up from 208 in Q4 2024.
- Funds reported $604M of Vir Biotechnology stock for Q1 2025, down 7.3% quarter-over-quarter.
- 52 funds opened new Vir Biotechnology positions in Q1 2025 and 26 closed out, a net change of +26 holders.
- The largest Vir Biotechnology buyer in Q1 2025 was Fidelity Investments, an estimated $19.6M added.
- The largest Vir Biotechnology seller in Q1 2025 was JP Morgan Chase, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2025.